| Literature DB >> 26831224 |
Yan Gu, Kan Zhai, Huan-Zhong Shi1.
Abstract
BACKGROUND: It is often challenging to distinguish tuberculous pleural effusion (TPE) from malignant pleural effusion (MPE); thoracoscopy is among the techniques with the highest diagnostic ability in this regard. However, such invasive examinations cannot be performed on the elderly, or on those in poor physical condition. The aim of this study was to explore the differential diagnostic value of carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and squamous cell carcinoma (SCC) associated antigen in patients with TPE and MPE.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26831224 PMCID: PMC4799566 DOI: 10.4103/0366-6999.174501
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Carbohydrate antigen 125, carbohydrate antigen 199, carcinoembryonic antigen, neuron-specific enolase and squamous cell carcinoma in patients with tuberculous pleural effusion and malignant pleural effusion
| Histological types | Tuberculosis | Adenocarcinoma | SCC | Small cell carcinoma | Mesothelioma |
|---|---|---|---|---|---|
| Serum | |||||
| CA125 (U/ml) | 74.42 (28.91–120.95) | 92.47 (35.27–197.03) | 171.40 (114.40–277.40) | 106.10 (55.64–152.90) | 47.30 (19.72–81.27) |
| A199 (U/ml) | 6.03 (3.04–10.79) | 15.99 (10.16–51.59) | 38.19 (28.87–39.34) | 17.49 (14.28–29.17) | 6.27 (5.68–15.60) |
| CEA (ng/ml) | 1.60 (1.10–2.15) | 6.35 (3.40–23.43) | 5.10 (4.30–26.90) | 2.60 (1.40–8.10) | 1.85 (1.50–2.50) |
| NSE (ng/ml) | 13.23 (11.99–17.27) | 14.34 (11.79–17.91) | 19.62 (16.53–21.12) | 52.25 (23.77–112.40) | 14.48 (13.18–15.89) |
| SCC (ng/ml) | 0.60 (0.40–0.80) | 0.60 (0.50–0.90) | 3.70 (3.10–5.10) | 1.00 (0.70–1.70) | 0.90 (0.60–1.10) |
| Pleural fluid | |||||
| CA125 (U/ml) | 277.00 (104.73–561.15) | 1172.00 (508.43–2244.75) | 616.90 (177.30–1108.00) | 932.00 (500.60–1590.00) | 383.30 (316.62–651.05) |
| CA199 (U/ml) | 2.93 (1.62–4.85) | 36.99 (6.97–198.17) | 8.55 (4.04–17.39) | 22.70 (6.01–129.40) | 3.39 (2.66–6.11) |
| CEA (ng/ml) | 1.20 (0.70–1.50) | 82.05 (15.17–487.30) | 3.90 (3.50–7.50) | 6.10 (2.00–48.00) | 1.10 (1.00–1.75) |
| NSE (ng/ml) | 8.57 (6.80–9.61) | 9.62 (7.57–10.93) | 10.72 (8.12–10.72) | 58.67 (21.64–132.17) | 8.62 (8.09–9.82) |
| SCC (ng/ml) | 0.70 (0.35–1.00) | 0.80 (0.70–1.37) | 15.10 (11.40–67.10) | 1.60 (1.00–2.50) | 1.00 (0.40–2.10) |
| P/S ratio | |||||
| CA125 | 3.07 (1.17–6.22) | 10.70 (4.78–22.50) | 2.76 (0.83–5.39) | 8.74 (3.65–16.66) | 11.90 (6.97–18.65) |
| CA199 | 0.53 (0.38–0.74) | 1.00 (0.41–3.89) | 0.46 (0.30–0.48) | 1.29 (0.44–3.20) | 0.50 (0.27–0.62) |
| CEA | 0.70 (0.55–0.91) | 7.52 (2.16–22.54) | 0.76 (0.75–0.81) | 3.36 (0.95–4.36) | 0.60 (0.44–0.74) |
| NSE | 0.56 (0.44–0.70) | 0.63 (0.49–0.80) | 0.51 (0.49–0.68) | 0.95 (0.87–1.12) | 0.60 (0.52–0.74) |
| SCC | 0.85 (0.68–1.34) | 1.36 (1.00–2.41) | 3.69 (3.08–4.70) | 1.47 (0.90–3.33) | 0.78 (0.50–2.17) |
Values are expressed as median and 25th–75th percentiles in parenthesis. CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; SCC: Squamous cell carcinoma; CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199; P/S: Pleural fluid concentration to serum concentration.
Clinical and radiological characteristics of patients with pleural effusion
| Characteristics | TPE ( | MPE ( | |||
|---|---|---|---|---|---|
| Percentage | Percentage | ||||
| Smoking | 15 | 42.86 | 41 | 43.16 | 0.975 |
| Dyspnea | 25 | 71.43 | 80 | 84.21 | 0.101 |
| Chest pain | 14 | 40.00 | 27 | 28.42 | 0.208 |
| Cough | 25 | 71.43 | 67 | 70.53 | 0.920 |
| Phlegm | 14 | 40.00 | 36 | 37.89 | 0.827 |
| Hemoptysis | 0 | 0.00 | 8 | 8.42 | 0.076 |
| Fever | 16 | 45.71 | 10 | 10.53 | <0.001 |
| Weight loss | 7 | 20.00 | 25 | 26.32 | 0.458 |
| Pulmonary atelectasis | 0.413 | ||||
| Obstructive atelectasis | 5 | 14.29 | 16 | 16.84 | |
| Compression atelectasis | 17 | 48.57 | 34 | 35.79 | |
| Mass | 1 | 2.86 | 1 | 1.05 | 0.458 |
| Single nodule | 0 | 0.00 | 38 | 40.00 | <0.001 |
| Multiple nodule | 2 | 5.71 | 16 | 16.84 | 0.103 |
| Infiltrated shadow | 6 | 17.14 | 28 | 29.47 | 0.156 |
| Cavity | 23 | 65.71 | 66 | 69.47 | 0.682 |
| Pleural nodules | 0 | 0.00 | 25 | 26.32 | <0.001 |
| Pleural thickening | 0.006 | ||||
| Local | 11 | 31.43 | 59 | 62.11 | |
| Diffusion | 11 | 31.43 | 13 | 13.68 | |
| Lymphadenectasis | 0.027 | ||||
| ≤1 cm | 17 | 48.57 | 38 | 40.00 | |
| >1 cm | 4 | 11.43 | 33 | 34.74 | |
| Laterality | 0.866 | ||||
| Left | 15 | 42.86 | 37 | 38.95 | |
| Right | 14 | 40.00 | 43 | 45.26 | |
| Bilateral | 6 | 17.14 | 15 | 15.79 | |
| Quantity | 0.683 | ||||
| <1/3 | 1 | 2.86 | 1 | 1.05 | |
| 1/3–2/3 | 7 | 20.00 | 16 | 16.84 | |
| >2/3 | 27 | 77.14 | 78 | 82.11 | |
TPE: Tuberculous pleural effusion; MPE: Malignant pleural effusion.
Diagnostic value of five tumour markers in serum, pleural effusion and the ratio of pleural effusion and serum for the discrimination between tuberculous pleural effusion and malignant pleural effusion
| TM | Cut-off value | AUC | Specificity (%) | Sensitivity (%) | Accuracy (%) | PLR | NLR | LR | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Serum | ||||||||||
| CA125 (U/ml) | 151.55 | 0.58 | 88.57 | 33.68 | 48.46 | 2.95 | 0.75 | 3.94 | 88.89 | 32.98 |
| CA199 (U/ml) | 9.88 | 0.76 | 74.29 | 67.37 | 69.23 | 2.62 | 0.44 | 5.96 | 87.67 | 45.61 |
| CEA (ng/ml) | 3.50 | 0.79 | 80.00 | 58.95 | 64.62 | 2.95 | 0.51 | 5.74 | 88.89 | 41.79 |
| NSE (ng/ml) | 13.27 | 0.58 | 54.29 | 70.53 | 66.15 | 1.54 | 0.54 | 2.84 | 80.72 | 40.43 |
| SCC (ng/ml) | 0.85 | 0.57 | 77.14 | 36.84 | 47.69 | 1.61 | 0.82 | 1.97 | 81.40 | 31.03 |
| Pleural fluid | ||||||||||
| CA125 (U/ml) | 644.3 | 0.78 | 82.86 | 61.05 | 66.92 | 3.56 | 0.47 | 7.58 | 90.62 | 43.94 |
| CA199 (U/ml) | 12.08 | 0.81 | 97.14 | 53.68 | 65.38 | 18.79 | 0.48 | 39.41 | 98.08 | 43.59 |
| CEA (ng/ml) | 3.35 | 0.86 | 94.29 | 74.74 | 80.00 | 13.08 | 0.27 | 48.81 | 97.26 | 57.89 |
| NSE (ng/ml) | 9.71 | 0.66 | 77.14 | 52.63 | 59.23 | 2.30 | 0.61 | 3.75 | 86.21 | 37.50 |
| SCC (ng/ml) | 1.35 | 0.69 | 91.43 | 36.84 | 51.54 | 4.30 | 0.69 | 6.22 | 92.11 | 34.78 |
| P/S ratio | ||||||||||
| CA125 | 5.93 | 0.75 | 74.29 | 67.37 | 69.23 | 2.62 | 0.44 | 5.96 | 87.67 | 45.61 |
| CA199 | 0.80 | 0.64 | 82.86 | 51.58 | 60.00 | 3.01 | 0.58 | 5.15 | 89.09 | 38.67 |
| CEA | 1.47 | 0.79 | 97.14 | 61.05 | 70.77 | 21.37 | 0.40 | 53.30 | 98.31 | 47.89 |
| NSE | 0.76 | 0.64 | 85.71 | 38.95 | 51.54 | 2.73 | 0.71 | 3.83 | 88.10 | 34.09 |
| SCC | 0.90 | 0.69 | 60.00 | 75.79 | 71.54 | 1.89 | 0.40 | 4.70 | 83.72 | 47.73 |
TM: Tumor marker; AUC: Area under the receiver operating characteristic curve; PLR: Positive likelihood ratio; NLR: Negative likelihood ratio; PPV: Positive predictive value; NPV: Negative predictive value; LR: Likelihood ratio; CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; SCC: Squamous cell carcinoma; P/S: Pleural fluid concentration to serum concentration.
Diagnostic value of combination of five tumor markers in serum, pleural effusion and the ratio of pleural effusion and serum for achieving the best diagnostic accuracy
| TM | Cut-off value | AUC | Specificity (%) | Sensitivity (%) | Accuracy (%) |
|---|---|---|---|---|---|
| Model 1 | 0.93 | 0.85 | 91.43 | 73.68 | 78.46 |
| Model 2 | 1.59 | 0.95 | 100.00 | 82.11 | 86.92 |
| Model 3 | 0.98 | 0.91 | 91.43 | 78.95 | 82.31 |
In Model 1: We evaluated all of five TMs in serum; in Model 2: We evaluated five TMs in pleural fluid; in Model 3: We evaluated all of the TMs in the P/S ratio. TM: Tumor marker; AUC: Area under the receiver operating characteristic curve; P/S: Pleural fluid concentration to serum concentration.
Figure 1In Model 1, we evaluated all five tumor markers in serum. In Model 2, we evaluated the five tumor markers in pleural fluid. In Model 3, the ratio of the tumor marker concentration in pleural fluid to that in serum was analyzed.